Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers

Summary

This phase I trial studies how well dolcanatide works in preventing colorectal cancer in healthy participants. Dolcanatide is similar to a natural hormone released into the intestine. It is thought that people who have low levels of the hormone are more likely to get colon cancer. It may be possible to prevent colon cancer by giving a drug that is similar to the hormone, such as dolcanatide.

Timeline

Start

2018-07-27

Primary completion

2019-01-02

Completion

2021-05-17

Outcome

Missed primary endpoint

registry analysis (superiority test); Arm B (Dolcanatide) vs Arm A (Placebo); p = 0.15; Wilcoxon (Mann-Whitney) NCT03300570 ↗

Drugs

Indications